Trial for Sandoz biosimilar hailed as ‘landmark’

Clinical data gathered for Sandoz’s biosimilar Etanercept (derived from Amgen and Pfizer’s Enbrel) was based from a “landmark” trial design in psoriasis in which over 500 patients switched from the original drug to the biosimilar. The data from the EGALITY trial showed the Novartis unit’s biosimilar, filed in the US and EU, met primary endpoint

Continue Reading